Hyperbaric oxygen therapy (HBOT) involves breathing 100% pure oxygen inside a pressurized chamber at 1.4–3.0 atmospheres absolute (ATA). At these pressures, oxygen dissolves directly into plasma at concentrations far exceeding normal hemoglobin-bound delivery — dramatically increasing oxygen availability to all tissues, including hypoxic tumor microenvironments. In cancer biology, tumor hypoxia is one of the most significant drivers of treatment resistance, metastasis, immune evasion, and aggressive disease behavior. HBOT targets this upstream bottleneck directly. The most strongly supported uses in oncology are radiation sensitization (head and neck cancer, with Cochrane-level evidence), management of late radiation tissue injury, and chemotherapy potentiation. The historical concern that HBOT promotes tumor growth has been thoroughly evaluated and refuted by multiple systematic reviews. HBOT is used daily in the SEED Program as a foundational terrain modifier — reducing the hypoxic conditions that drive cancer progression and enhancing the efficacy of every other therapy delivered alongside it.
This question is addressed first because it is the most common reason oncologists have historically denied cancer patients access to HBOT. It deserves a direct and evidence-based answer before any other discussion.
The concern that HBOT might promote tumor growth originated in a 1966 case series by Johnson and Lauchlan in which patients treated with HBOT as a radiation sensitizer appeared to show an unusual pattern of metastases. This observation — from a small, uncontrolled case series — sparked decades of caution in mainstream oncology. The underlying theoretical mechanism was plausible: oxygen is required for angiogenesis and wound healing, and tumor cells are cells; therefore, might oxygen accelerate tumor proliferation?
Multiple systematic reviews specifically designed to answer this question have now been published, spanning clinical reports, animal models, and cell culture studies from 1966 through 2025. Their collective conclusion is consistent:
Feldmeier et al. (2003) — the landmark review in Undersea and Hyperbaric Medicine that formally addressed the concern: no evidence that HBOT acts as a stimulator of tumor growth or an enhancer of recurrence; in some cases, tumor inhibitory effects were observed
Daruwalla & Christophi (2006) — reviewed HBO and cancer literature comprehensively; concluded the use of HBOT in patients with malignancies is safe
Systematic review (2004–2012) — updated the Feldmeier analysis; no evidence that HBOT stimulates tumor growth or enhances recurrence; evidence that HBOT may have tumor-inhibitory effects in certain cancer subtypes
Safety evaluation — active solid tumors (2025) — retrospective analysis of cancer patients with solid tumors receiving at least 5 HBOT sessions; no evidence found to suggest HBOT contributes to tumor progression, recurrence, or metastasis
The mechanistic explanation for why HBOT does not promote tumor growth — and may in fact inhibit it — lies in the biology of tumor hypoxia itself. Cancer cells that thrive in hypoxic environments have adapted to exploit low oxygen: upregulating HIF-1α, driving angiogenesis, suppressing apoptosis, and evading immune surveillance. These are pro-tumor adaptations to hypoxia. Relieving hypoxia through HBOT disrupts these adaptations. HBOT also increases reactive oxygen species (ROS) selectively in cancer cells with impaired antioxidant defenses — creating a pro-apoptotic environment analogous to the mechanism of IV Vitamin C.
The only absolute contraindication to HBOT is an untreated pneumothorax. Active malignancy is not a contraindication to HBOT. The fear that HBOT promotes tumor growth or recurrence is not supported by the published evidence, and cancer patients should not be denied HBOT on this basis. This represents a significant clinical misperception that has limited patient access to a safe and potentially beneficial therapy for decades.
At sea level, approximately 97% of oxygen is carried by hemoglobin; only ~0.3 mL O₂ per 100 mL plasma is dissolved. At 3.0 ATA with 100% oxygen, dissolved plasma oxygen increases to approximately 6 mL per 100 mL — sufficient to sustain tissue oxygenation independent of hemoglobin. This hyperoxic state dramatically elevates pO₂ in tumor tissues, which under hypoxic conditions may have pO₂ as low as 5 mmHg. HBOT can raise intratumoral pO₂ to 30–50 mmHg — a 6–10 fold increase that fundamentally alters the tumor microenvironment.
Hypoxia-inducible factor 1-alpha (HIF-1α) is the central transcription factor through which cancer cells adapt to and exploit low-oxygen conditions. When active, HIF-1α drives a broad transcriptional program promoting tumor survival, angiogenesis, glycolytic metabolism, immune evasion, invasion, and metastasis. HIF-1α is arguably the most important upstream driver of aggressive cancer behavior in the tumor microenvironment.
HBOT directly inhibits HIF-1α activity by restoring intratumoral oxygen tension. When pO₂ is elevated, the oxygen-dependent prolyl hydroxylases that normally tag HIF-1α for proteasomal degradation become active again — destabilizing and clearing HIF-1α. This blocks the entire downstream transcriptional program that HIF-1α drives, reducing metabolic adaptability, suppressing hypoxia-driven angiogenesis, and re-sensitizing cancer cells to apoptosis and treatment.
Oxygen is a critical radiosensitizer — the 'oxygen enhancement ratio' (OER) is well established in radiobiology. Ionizing radiation generates free radicals that cause DNA strand breaks; in the presence of oxygen, these breaks are 'fixed' and become irreversible. In hypoxic tumors, the absence of oxygen allows cancer cells to repair radiation-induced DNA damage, dramatically reducing radiation efficacy. HBOT administered before or during radiation therapy raises intratumoral pO₂, restoring radiosensitivity in previously radiation-resistant hypoxic cells.
For chemotherapy, HBOT improves drug delivery to hypoxic tumor regions through increased perfusion and vascular normalization. A 2024 Cell Stem Cell study found HBOT downregulates CD44v6 expression on cancer stem cells (CSCs) — increasing their uptake of chemotherapy drugs by 2.8 times while reducing their metastatic potential. This is a clinically significant finding: cancer stem cells are among the most treatment-resistant cell populations and a primary driver of relapse.
Paradoxically, while HBOT increases oxygenation, it also reduces pathological tumor angiogenesis — the chaotic, dysfunctional vasculature that cancer cells build to sustain themselves in hypoxic conditions. By removing the hypoxic stimulus that drives HIF-1α-mediated angiogenesis, HBOT shifts tumor vasculature toward a more normal, functional phenotype. This vascular normalization improves drug delivery, immune cell infiltration, and overall treatment efficacy — without stimulating the uncontrolled neovascularization that characterizes tumor progression.
Tumor hypoxia suppresses immune surveillance through multiple mechanisms: reducing NK cell and T-cell function, promoting immunosuppressive M2 macrophage polarization, and creating a metabolic environment hostile to immune effector cells. HBOT reverses these effects by restoring oxygen availability in the tumor microenvironment, allowing immune cells to function more effectively. This synergizes directly with mistletoe therapy's NK cell activation and macrophage polarization effects within the SEED protocol.
Cancer stem cells (CSCs) represent the most treatment-resistant subpopulation within tumors — responsible for recurrence, metastasis, and therapy failure. CSCs frequently reside in hypoxic niches that protect them from conventional treatment. The 2024 Cell Stem Cell study demonstrating HBOT-mediated CD44v6 downregulation — increasing chemotherapy uptake 2.8-fold while reducing metastatic capacity — suggests a direct therapeutic effect on the cell population most responsible for long-term treatment failure.
The physics of hyperbaric oxygen delivery and intratumoral oxygenation are well established. HIF-1α inhibition by HBOT is strongly supported mechanistically and in preclinical models. Radiation sensitization has the strongest clinical evidence base — Cochrane-level. Chemotherapy potentiation is supported by preclinical and emerging clinical data. Cancer stem cell effects via CD44v6 are a promising 2024 finding requiring further clinical validation.
The same A–D evidence grade framework used throughout the SEED Evidence Series is applied here.
| Grade | Level | Description |
|---|---|---|
| A | Strong | Multiple RCTs or meta-analyses with consistent results |
| B | Moderate | Limited RCTs, prospective cohorts, or phase II trials with positive signal |
| C | Emerging | Phase I trials, uncontrolled studies, strong preclinical data; promising but not definitive |
| D | Limited | Case reports, mechanistic rationale only, or conflicting results |
| Study | Key Finding | Grade |
|---|---|---|
| Bennett et al. — Cochrane Review (2018) HBOT as Radiation Sensitizer Head & Neck Cancer | Systematic review of HBOT combined with radiotherapy across multiple cancer types. Evidence that HBOT improves local tumor control, mortality, and local recurrence for head and neck cancers. Benefits may depend on fractionation scheme. Cautions that more large RCTs are needed. Most important: Cochrane-level evidence that HBOT enhances radiation efficacy. | A |
| Medical Research Council Trials (30-year summary) Head & Neck and Cervical Cancer Radiosensitization | Five UK MRC randomized trials comparing standard radiotherapy in air vs. hyperbaric oxygen across multiple solid tumor types. Demonstrated improved local cure and survival in head and neck and cervical cancer with HBOT radiosensitization. One of the largest clinical data sets in HBOT oncology. | A |
| Meier et al. — Systematic Review (2023) Breast Cancer Late Radiation Toxicity | Systematic review of HBOT for late radiation toxicity in breast cancer. Improvements in fibrosis, lymphedema (3 of 4 studies showed reduction), pain, and tissue healing. Supports HBOT as an effective management strategy for long-term radiation complications — highly relevant for SEED patients who have undergone prior radiation. | B |
| HOT2 — Phase 3 RCT (2022) Pelvic Radiation Bowel Dysfunction Post-Radiation Injury | Double-blind, sham-controlled Phase 3 RCT in patients with chronic bowel dysfunction after pelvic radiotherapy. Notably, this trial did NOT meet its primary endpoint — an important result to acknowledge honestly. Highlights that HBOT's benefit in radiation injury may be condition- and endpoint-specific. | B |
| Safety Evaluation — Active Solid Tumors (2025) Retrospective Analysis Oncology Safety | Retrospective analysis of cancer patients with solid tumors who received at least 5 HBOT sessions. Comprehensive outcome data collected including recurrence, metastasis, and mortality. No evidence found that HBOT contributes to tumor progression, recurrence, or metastasis. Directly addresses the primary clinical concern. | B |
| Cell Stem Cell Study (2024) Cancer Stem Cells Chemosensitization | HBOT downregulates CD44v6 expression on cancer stem cell surfaces. Effect: 2.8-fold increase in chemotherapy drug uptake and reduced metastatic capacity. Significant finding — CSCs are the most treatment-resistant population and a primary driver of relapse. Clinical validation needed. | C |
| Lung Cancer Xenograft Model A549 Cell Line Preclinical Mechanism | HBOT suppressed A549 lung cancer cell growth in time-dependent manner. Improved tumor hypoxia, increased caspase-3-mediated apoptosis, and enhanced PECAM-1/CD31 (vascular normalization). HIF-1α downregulation confirmed. Establishes in vivo mechanistic basis for HBOT anti-tumor effects. | C |
| Feldmeier et al. — Systematic Review (2003) HBOT and Malignancy Tumor Growth Safety | The definitive systematic review addressing tumor growth concern. Comprehensive evaluation of clinical reports, animal studies, and cell culture data. Conclusion: no evidence HBOT stimulates tumor growth or enhances recurrence; in some cases tumor-inhibitory effects observed. Foundational safety reference for HBOT in oncology. | B |
Strongly supported: Radiation sensitization in head and neck cancer. Cochrane-level evidence across multiple RCTs. This is the strongest evidence base in HBOT oncology and the most compelling argument for HBOT as a treatment enhancer.
Strongly supported: Management of late radiation tissue injury. Multiple systematic reviews support HBOT for osteoradionecrosis, radiation proctitis, radiation cystitis, and breast radiation toxicity. Highly relevant for cancer patients in SEED with prior radiation history.
Strongly supported: Safety in active malignancy. Multiple systematic reviews spanning decades explicitly conclude HBOT does not promote tumor growth, recurrence, or metastasis.
Moderately supported: Chemotherapy potentiation. Improving drug delivery to hypoxic tumor regions, with CSC sensitization data emerging (2024). Mechanistically compelling; clinical RCT data still limited.
Moderately supported: HIF-1α inhibition and tumor microenvironment modification. Well established mechanistically and in preclinical models; clinical correlates are being established.
Honest caveat — HOT2 trial: The 2022 Phase 3 RCT in pelvic radiation bowel dysfunction did not meet its primary endpoint. This is a meaningful negative result that cautions against overgeneralizing HBOT's benefit in radiation injury across all conditions and endpoints. Evidence is condition-specific.
Not yet established: Survival benefit as monotherapy across cancer types. HBOT in oncology is best understood as a treatment enhancer — it improves the efficacy of radiation, chemotherapy, and immune therapies — not as a standalone anti-cancer agent.
The honest summary: HBOT is safe in active malignancy, has Cochrane-level evidence as a radiation sensitizer, strong evidence for radiation injury management, and growing mechanistic and early clinical evidence as a chemotherapy potentiator and tumor microenvironment modifier. It is correctly positioned in SEED as a daily foundational therapy that enhances the environment in which all other treatments operate.
In the SEED 1-week intensive, HBOT is administered daily — Monday through Friday — making it the highest-frequency therapy in the protocol. This reflects its role not as an intermittent intervention but as a continuous terrain modifier that creates and maintains the biological conditions in which all other SEED therapies operate more effectively.
By reducing tumor hypoxia daily, HBOT directly supports the mechanism of every other core therapy: IV Vitamin C's pro-oxidant H₂O₂ generation is amplified in an oxygenated microenvironment; mistletoe's NK cell activation operates more effectively when immune cells are not suppressed by hypoxia; ozone therapy's oxidative preconditioning synergizes with HBOT's ROS generation; hyperthermia's vascular effects are enhanced by normalized tumor perfusion; and terrain support medications penetrate hypoxic tumor regions more effectively when HBOT improves vascular delivery.
HBOT is best understood in SEED not as a therapy that does one thing well, but as the foundational condition-setter for everything else. A hypoxic tumor microenvironment is resistant to oxidative therapies, immune therapies, heat therapies, and drug delivery. Daily HBOT removes that resistance — creating an oxygen-rich, vascular-normalized, HIF-1α-suppressed environment in which the other five core therapies can operate at full effect.
Pressure — typically 1.5–2.4 ATA; specific pressure per clinical judgment and equipment availability
Duration — approximately 60–90 minutes per session
Frequency in SEED — daily — Monday through Friday during the 1-week intensive
Oxygen — 100% pure oxygen breathed throughout the session
Chamber type — monoplace (single-patient) or multiplace; both deliver equivalent physiological effect at equivalent pressures
As the daily foundational therapy, HBOT creates the baseline oxygenated environment in which other same-day therapies are delivered. Where logistically possible, scheduling HBOT earlier in the treatment day maximizes the window of elevated intratumoral pO₂ during which other therapies are administered. The 30-minute post-HBOT window of elevated intratumoral oxygen is particularly relevant for any radiation or oxidative therapies delivered on the same day.
A significant proportion of SEED patients will have received prior radiotherapy. HBOT has its strongest evidence base specifically in this population — for both late radiation tissue injury management (osteoradionecrosis, radiation fibrosis, lymphedema, radiation bowel injury) and as a resensitizer for any ongoing or future radiation treatment. In patients with radiation-damaged tissue, HBOT's angiogenic and collagen synthesis support also contributes to tissue repair and functional recovery.
Tumor hypoxia is one of the most powerful and well-characterized terrain conditions that enables cancer progression. It drives HIF-1α-mediated metabolic reprogramming, immune evasion, angiogenesis, resistance to conventional treatment, and metastasis. A terrain-first integrative oncology approach cannot ignore hypoxia — and HBOT is the only widely available clinical tool specifically designed to address it. In the SEED framework, HBOT represents the foundational terrain intervention: before immunotherapy can activate, before oxidative therapies can work, before chemotherapy can reach its target, the terrain must be hospitable. HBOT creates that condition.
HBOT has an excellent safety profile and is one of the lowest-risk procedures in medicine when properly administered. The only absolute contraindication is untreated pneumothorax.
| Consideration | Clinical Detail | Management |
|---|---|---|
| Untreated Pneumothorax (ABSOLUTE) | Pressurization with an untreated pneumothorax can precipitate life-threatening tension pneumothorax during ascent. This is the only absolute contraindication to HBOT. | Chest X-ray or CT required if pneumothorax is suspected before any HBOT session. Treat pneumothorax before initiating HBOT. |
| Oxygen Toxicity (CNS / Pulmonary) | At high pressures (>3 ATA) or prolonged exposures, CNS oxygen toxicity can occur (seizure, visual disturbances). Pulmonary oxygen toxicity can develop with prolonged daily sessions. Both are rare at standard therapeutic pressures and durations. | Use standard therapeutic pressures (1.5–2.4 ATA). Standard 60–90 minute sessions with air breaks reduce pulmonary oxygen toxicity risk. CNS toxicity is rare at pressures below 2.4 ATA. |
| Middle Ear and Sinus Barotrauma | Pressure equalization in middle ear and sinuses is required during descent and ascent. Patients with upper respiratory congestion, Eustachian tube dysfunction, or recent sinus surgery are at risk. | Teach Valsalva equalization before first session. Delay HBOT during acute upper respiratory illness. Decongestants may be used if clinically appropriate. Tympanostomy tubes may be considered for chronic equalization difficulty. |
| Claustrophobia | Monoplace chambers enclose the patient. Patients with significant claustrophobia may not tolerate the procedure. | Multiplace chambers provide a more open environment. Mild anxiolysis may be appropriate. Screen for claustrophobia before first session. |
| Cardiac and Pulmonary Conditions | HBOT increases systemic vascular resistance and can reduce cardiac output. Patients with severe congestive heart failure, severe COPD, or significant air-trapping lung disease require careful evaluation. | Cardiopulmonary clearance for patients with significant cardiac or pulmonary history. Discuss with cardiologist if relevant. COPD is a relative contraindication requiring individualized risk-benefit assessment. |
| Implanted Devices | Some implanted devices (certain pacemakers, drug infusion pumps) may be affected by pressure changes. Medical device compatibility must be confirmed before HBOT. | Verify compatibility of all implanted devices with HBOT pressure range before initiating treatment. |
| Certain Chemotherapy Agents | Bleomycin and doxorubicin have documented interactions with HBOT — bleomycin in particular can cause severe pulmonary toxicity when combined with HBOT. Disulfiram may also interact. | Review complete chemotherapy history. Avoid HBOT in patients currently receiving or recently treated with bleomycin. Use caution with doxorubicin. Coordinate timing with oncologist. |
| Pregnancy | HBOT safety in pregnancy is not well established; generally considered relatively contraindicated except in life-threatening emergencies. | Avoid HBOT during pregnancy unless benefit clearly outweighs risk in emergency context. |
HBOT earns its place as the daily foundational therapy in the SEED Program for the following reasons:
Tumor hypoxia is a primary terrain driver of cancer progression — it enables HIF-1α-mediated resistance, immune evasion, metabolic reprogramming, and metastasis; HBOT is the only clinical tool designed specifically to address it
Cochrane-level evidence for radiation sensitization — the strongest evidence base among all SEED therapies for a specific measurable anti-tumor outcome
Platform effect — daily HBOT creates the oxygenated, vascular-normalized microenvironment in which all other SEED therapies — IV Vitamin C, mistletoe, ozone, hyperthermia, terrain support medications — operate more effectively
Safety in active malignancy definitively established — multiple systematic reviews across decades; the tumor growth concern is resolved; active malignancy is not a contraindication
Radiation injury management — high clinical relevance for the SEED patient population, many of whom will have prior radiation history
Cancer stem cell sensitization — emerging 2024 data on CD44v6 downregulation and chemotherapy uptake — targeting the most treatment-resistant cell population
Daily frequency is practical and well-tolerated — 60–90 minute sessions fit within the SEED intensive schedule; adverse event profile is manageable and predictable
Bennett MH, Feldmeier J, Smee R, Milross C. Hyperbaric oxygenation for tumour sensitisation to radiotherapy. Cochrane Database Syst Rev. 2018;4(4):CD005007.
Feldmeier JJ, Carl U, Hartmann K, Sminia P. Hyperbaric oxygen: does it promote growth or recurrence of malignancy? Undersea Hyperb Med. 2003;30(1):1–18.
Daruwalla J, Christophi C. Hyperbaric oxygen therapy for malignancy: a review. World J Surg. 2006;30(12):2112–2131.
Overgaard J, et al. Hyperbaric oxygen as a radiation sensitizer in head and neck cancer: 30-year summary of the UK Medical Research Council trials. Radiother Oncol. 1997.
Meier EL, Mink van der Molen DR, Lansdorp CA, et al. Hyperbaric oxygen therapy for local late radiation toxicity in breast cancer patients: a systematic review. Breast. 2023;67:46–54.
Horsman MR, Overgaard J. The impact of hypoxia and its modification of the outcome of radiotherapy. J Radiat Res. 2016;57(S1):i90–i98.
Zhuang Y, Liu K, He Q, et al. Exploring a new direction in targeted cancer therapy through HBOT combined with biomedical engineering techniques. Front Oncol. 2025;15:1580515.
Lin Z, Bennett MH, Hawkins GC, et al. Hyperbaric oxygen therapy for late radiation tissue injury. Cochrane Database Syst Rev. 2023;8:CD005005.
Stępień K, Ostrowski RP, Matyja E. Hyperbaric oxygen as adjunctive therapy in treatment of malignancies, including brain tumours. Med Oncol. 2016;33(9):101.
Poff AM, Ward N, Seyfried TN, Arnold P, D'Agostino DP. Non-toxic metabolic management of metastatic cancer in VM mice: novel combination of ketogenic diet, ketone supplementation, and hyperbaric oxygen therapy. PLoS One. 2013;8(6):e65522.
StatPearls. Hyperbaric Oxygen Therapy Contraindications. NCBI Bookshelf. Updated 2025.
Cell Stem Cell. HBOT downregulates CD44v6 on cancer stem cells, increasing chemotherapy uptake 2.8-fold and reducing metastatic capacity. 2024.
National Cancer Institute. Hyperbaric Oxygen Therapy (PDQ) — Health Professional Version. NCI. 2024.
This white paper is prepared for clinical and provider education purposes as part of the Root Causes SEED Program Evidence Series. It summarizes published research and does not constitute medical advice. All clinical decisions should be individualized by a qualified provider. Evidence grades reflect the authors' assessment of the published literature at time of writing and will be updated as new research emerges.